Press

Numinus to Participate in the KCSA Mental Health Virtual Investor Conference on December 15, 2022

Dec 14 • 2 min read

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will present at the KCSA Mental Health Investor Conference to be held at VirtualInvestorConferences.com on Thursday, December 15, 2022 at 12:30 p.m. ET / 9:30 a.m. PT. This will be a live, interactive…

Field Trip Health & Wellness To Webcast Live at the KCSA Mental Health Conference on December 15th

Dec 14 • 2 min read

Field Trip Health & Wellness Ltd. (TSXV: FTHW), a global leader in the delivery of psychedelic therapies, today announced that Ronan Levy, Chairman & Chief Executive Officer of Field Trip Health & Wellness, will webcast live at the KCSA Mental Health Conference, hosted by VirtualInvestorConferences.com, on Thursday, December 15th, 2022. DATE: December 15, 2022TIME: 11:00 a.m. ETLINK: https://bit.ly/3Ub0iE3 A recording…

Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor

Dec 14 • 3 min read

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being is pleased to announce that it has closed the second tranche of its previously announced private placement of up to CAD$3 million. The Company has issued 7,751,859 common shares at a price of…

Small Pharma To Support University College London Research Project on Neuroplasticity

Dec 14 • 2 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it will provide its drug candidate SPL026, an intravenous formulation of the psychedelic drug N, N-dimethyltryptamine, to support a University College London led study investigating induced brain changes and neuroplasticity following intravenous…

Palo Alto IV Ketamine Depression Therapy Launched By Soft Reboot Wellness

Dec 14 • 3 min read

Soft Reboot Wellness’ expanded ketamine therapy is offered in response to growing calls for more effective approaches to major depressive disorder. Led by board-certified anesthesiologist Dr. Sara Herman MD, Soft Reboot Wellness utilizes the scientific basis behind ketamine’s promise as a tool or catalyst to help heal from depression. More details can be found at https://www.softrebootwellness.com/how-does-ketamine-help-where-antidepressants-dont…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441